CTRI/2023/07/055109
Not Yet Recruiting
N/A
PSMA PET radiomics for prostate cancer risk stratification; a machine learning approach
Dept of nuclear medicine0 sites0 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Health Condition 1: C61- Malignant neoplasm of prostate
- Sponsor
- Dept of nuclear medicine
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Patients with age \>\= 18 years
- •2\)Biopsy proven prostate cancer
- •3\)Biopsies performed at least 4 weeks prior to 68Ga\-PSMA\-11 PET/CT, or after 68Ga\-PSMA PET/CT
Exclusion Criteria
- •1\)Patients without pathological confirmation of prostate cancer
- •2\)Patients who have received prior treatment or are receiving any form of treatment
- •3\)Patients with no PSA assay
- •4\)History of allergy to components of 68Ga\-PSMA\-11 or compounds of similar chemical characteristics
- •5\)Patients with other known malignancies, both active and treated
- •6\)Refusal to give informed written consent (for patients enrolled prospectively)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
Phase 1
PSMA-PET/CT for prostate cancerEUCTR2017-003461-96-BEGhent University Hospital72
Recruiting
N/A
PSMA PET prostate cancer registration studyProstate cancerNL-OMON28640-
Recruiting
Phase 3
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate CancerProstate CancerNCT03594760Centre hospitalier de l'Université de Montréal (CHUM)1,000
Active, Not Recruiting
Phase 1
18F-PSMA PET in primary prostate cancer.75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients with PIRADS 3 (equivocal disease) and 25 patients with PIRADS 4-5 (highly suspicious for malignancy) will be included in this explorative study.MedDRA version: 20.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-001387-28-NLRadboud University Medical Center75
Completed
Phase 2
18F-PSMA-1007 PET to detect primary prostate cancer: a comparative study with mpMRI and correlation to histopathologyNL-OMON49534Radboud Universitair Medisch Centrum75